Abstract

Imaging strategies to monitor chimeric antigen receptor (CAR) T-cell biodistribution and proliferation harbor the potential to facilitate clinical translation for the treatment of both liquid and solid tumors. In addition, the potential adverse effects of CAR T cells highlight the need for mechanisms to modulate CAR T-cell activity. The herpes simplex virus type 1 thymidine kinase (HSV1-tk) gene has previously been translated as a PET reporter gene for imaging of T-cell trafficking in patients with brain tumor. The HSV1-TK enzyme can act as a suicide gene of transduced cells through treatment with the prodrug ganciclovir. Here we report the molecular engineering, imaging, and ganciclovir-mediated destruction of B7H3 CAR T cells incorporating a mutated version of the HSV1-tk gene (sr39tk) with improved enzymatic activity for ganciclovir. The sr39tk gene did not affect B7H3 CAR T-cell functionality and in vitro and in vivo studies in osteosarcoma models showed no significant effect on B7H3 CAR T-cell antitumor activity. PET/CT imaging with 9-(4-[18F]-fluoro-3-[hydroxymethyl]butyl)guanine ([18F]FHBG) of B7H3-sr39tk CAR T cells in an orthotopic model of osteosarcoma revealed tumor homing and systemic immune expansion. Bioluminescence and PET imaging of B7H3-sr39tk CAR T cells confirmed complete tumor ablation with intraperitoneal ganciclovir administration. This imaging and suicide ablation system can provide insight into CAR T-cell migration and proliferation during clinical trials while serving as a suicide switch to limit potential toxicities. SIGNIFICANCE: This study showcases the only genetically engineered system capable of serving the dual role both as an effective PET imaging reporter and as a suicide switch for CAR T cells.

Highlights

  • Chimeric antigen receptor (CAR) T cells allow for specific tumor antigen recognition via antibody-derived single-chain variable fragments

  • In vitro coculture assays demonstrated similar antitumor efficacy between the B7H3-sr39tk and B7H3 CAR T cells against 143B osteosarcoma cells naturally expressing B7H3 or Nalm6 leukemia cells engineered to overexpress B7H3 (Fig. 2C)

  • We have demonstrated that the sr39tk system can provide non-invasive monitoring and ablation of transferred CAR T cells

Read more

Summary

Introduction

Chimeric antigen receptor (CAR) T cells allow for specific tumor antigen recognition via antibody-derived single-chain variable fragments. Numerous clinical trials have utilized CARs to redirect T cells against targeted tumor antigens, with CD19-targeting CAR T cells achieving high complete response rates against therapy-resistant B-cell malignancies [1,2,3,4,5]. Imaging strategies to monitor CAR T-cell biodis-. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call